Cover Image
Market Research Report

Asia-Pacific Anti-Nuclear Antibody Test Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025

Published by Data Bridge Market Research Private Limited Product code 610297
Published Content info 248 Pages
Delivery time: 1-2 business days
Price
Back to Top
Asia-Pacific Anti-Nuclear Antibody Test Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025
Published: February 18, 2018 Content info: 248 Pages
Description

The Asia-Pacific anti-nuclear antibody test market is expected to reach USD 394.58 million by 2025, from USD 211.03 million in 2017 growing at a CAGR of 8.2% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

The major factors driving the growth of this market are increasing incidence of autoimmune diseases, rising medical insurance, and rise in government healthcare protection.

The key market players for Asia-Pacific anti-nuclear antibody test market are listed below:

  • Bio-Rad Laboratories, Inc.
  • Alere, Inc.
  • Trinity Biotech
  • Thermo Fisher Scientific Inc.
  • Antibodies Inc.
  • EUROIMMUN AG
  • Immuno Concepts

The market is further segmented into:

  • Product
  • Test
  • Disease
  • End-user

The Asia-Pacific anti-nuclear antibody test market is segmented on the basis of product into assay kits & reagents, systems, and software. In 2018, assay kits & reagents is expected to dominate the Asia-Pacific anti-nuclear antibody test market with 54.8% market share and is expected to reach USD 219.73 million by 2025, with the highest CAGR of 8.5% in the forecast period 2018 to 2025.

The Asia-Pacific anti-nuclear antibody test market is segmented on the basis of test into indirect immunofluorescence, ELISA, and multiplex testing. In 2018, indirect immunofluorescence is expected to dominate the Asia-Pacific anti-nuclear antibody test market with 53.0% market share and is expected to reach USD 200.17 million by 2025, with the CAGR of 7.6% in the forecast period 2018 to 2025. However, multiplex testing market segment is expected to grow at the highest CAGR of 9.5% in the forecast period, and is expected to reach USD 77.98 million in 2025 from USD 38.15 million in 2017.

The Asia-Pacific anti-nuclear antibody test market is segmented on the basis of disease into systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, scleroderma, polymyositis, and others. In 2018, systemic lupus erythematosus is expected to dominate the Asia-Pacific anti-nuclear antibody test market with 33.6% market share and is expected to reach USD 138.17 million by 2025, with the highest CAGR of 8.9% in the forecast period 2018 to 2025.

The Asia-Pacific anti-nuclear antibody test market is segmented on the basis of end-user into hospitals, clinics, physician office laboratories, and others. In 2018, hospitals is expected to dominate the Asia-Pacific anti-nuclear antibody test market with 48.3% market share and is expected to reach USD 193.92 million by 2025, with the highest CAGR of 8.5% in the forecast period 2018 to 2025.

Based on geography, the Asia-Pacific anti-nuclear antibody test market is segmented into geographical regions, such as,

  • Germany,
  • China,
  • Japan,
  • India,
  • South Korea,
  • Australia,
  • Thailand,
  • Malaysia,
  • Singapore,
  • Indonesia,
  • Philippines,
  • Rest of Asia-Pacific

Covered in this report:

The report covers the present scenario and the growth prospects of the Asia-Pacific anti-nuclear antibody test for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. OVERVIEW OF ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET
  • 1.4. CURRENCY AND PRICING
  • 1.5. LIMITATION
  • 1.6. MARKETS COVERED

2. MARKET SEGMENTATION

  • 2.1. MARKETS COVERED
  • 2.2. GEOGRAPHIC SCOPE
  • 2.3. YEARS CONSIDERED FOR THE STUDY
  • 2.4. CURRENCY AND PRICING
  • 2.5. RESEARCH METHODOLOGY
  • 2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7. SECONDARY SOURCES
  • 2.8. ASSUMPTIONS

3. MARKET OVERVIEW

  • 3.1. DRIVERS
    • 3.1.1. INCREASING INCIDENCE OF AUTOIMMUNE DISEASES
    • 3.1.2. RISING MEDICAL INSURANCE
    • 3.1.3. RISE IN GOVERNMENT HEALTHCARE PROTECTION
  • 3.2. RESTRAINTS
    • 3.2.1. STRICT REGULATION FOR PRODUCT APPROVAL
  • 3.3. OPPORTUNITIES
    • 3.3.1. INCREASING GROWTH IN HEALTHCARE EXPENDITURE
    • 3.3.2. EMERGING MARKETS
    • 3.3.3. LABORATORY AUTOMATION FAVORS THE MARKET
  • 3.4. CHALLENGES
    • 3.4.1. LACK OF SKILLED PROFESSIONALS

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET, BY PRODUCT

  • 6.1. OVERVIEW
  • 6.2. ASSAY KITS & REAGENTS
  • 6.3. SYSTEMS
  • 6.4. SOFTWARE

7. ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST

  • 7.1. OVERVIEW
  • 7.2. INDIRECT IMMUNOFLUORESCENCE
  • 7.3. ELISA
  • 7.4. MULTIPLEX TESTING

8. ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET, BY DISEASE

  • 8.1. OVERVIEW
  • 8.2. RHEUMATOID ARTHRITIS
  • 8.3. SYSTEMIC LUPUS ERYTHEMATOSUS
  • 8.4. SJOGREN'S SYNDROME
  • 8.5. SCLERODERMA
  • 8.6. POLYMYOSITIS
  • 8.7. OTHERS

9. ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET, BY END USER

  • 9.1. OVERVIEW
  • 9.2. HOSPITALS
  • 9.3. CLINICS
  • 9.4. PHYSICIAN OFFICE LABORATORIES
  • 9.5. OTHERS

10. ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET, BY GEOGRAPHY

  • 10.1. OVERVIEW
  • 10.2. ASIA-PACIFIC
    • 10.2.1. CHINA
    • 10.2.2. JAPAN
    • 10.2.3. INDIA
    • 10.2.4. SOUTH KOREA
    • 10.2.5. AUSTRALIA
    • 10.2.6. SINGAPORE
    • 10.2.7. THAILAND
    • 10.2.8. MALAYSIA
    • 10.2.9. INDONESIA
    • 10.2.10. PHILIPPINES
    • 10.2.11. REST OF ASIA-PACIFIC

11. ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET,

COMPANY LANDSCAPE 220

  • 11.1. COMPANY SHARE ANALYSIS: ASIA-PACIFIC
  • 11.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 11.3. COMPANY SHARE ANALYSIS: EUROPE
  • 11.4. COMPANY SHARE ANALYSIS: ASIA PACIFIC

12. COMPANY PROFILES

  • 12.1. THERMO FISHER SCIENTIFIC INC.
    • 12.1.1. COMPANY OVERVIEW
    • 12.1.2. THERMO FISHER SCIENTIFIC INC.:REVENUE ANALYSIS
    • 12.1.3. PRODUCT PORTFOLIO
    • 12.1.4. RECENT DEVELOPMENTS
  • 12.2. MERCK KGAA
    • 12.2.1. COMPANY OVERVIEW
    • 12.2.2. MERCK KGAA: REVENUE ANALYSIS
    • 12.2.3. PRODUCT PORTFOLIO
    • 12.2.4. RECENT DEVELOPMENTS
  • 12.3. ALERE INC.
    • 12.3.1. COMPANY OVERVIEW
    • 12.3.2. ALERE INC.: REVENUE ANALYSIS
    • 12.3.3. PRODUCT PORTFOLIO
    • 12.3.4. RECENT DEVELOPMENTS
  • 12.4. TRINITY BIOTECH
    • 12.4.1. COMPANY OVERVIEW
    • 12.4.2. TRINITY BIOTECH: COMPANY OVERVIEW
    • 12.4.3. PRODUCT PORTFOLIO
    • 12.4.4. RECENT DEVELOPMENTS
  • 12.5. ANTIBODIES INC.
    • 12.5.1. COMPANY OVERVIEW
    • 12.5.2. ANTIBODIES INC.: REVENUE ANALYSIS
    • 12.5.3. PRODUCT PORTFOLIO
    • 12.5.4. RECENT DEVELOPMENTS
  • 12.6. BIO-RAD LABORATORIES, INC.
    • 12.6.1. COMPANY OVERVIEW
    • 12.6.2. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
    • 12.6.3. PRODUCT PORTFOLIO
    • 12.6.4. RECENT DEVELOPMENTS
  • 12.7. EUROIMMUN AG (A SUBSIDIARY OF PERKINELMER INC.)
    • 12.7.1. COMPANY OVERVIEW
    • 12.7.2. PERKINELMER INC.: REVENUE ANALYSIS
    • 12.7.3. PRODUCT PORTFOLIO
    • 12.7.4. RECENT DEVELOPMENTS
  • 12.8. IMMUNO CONCEPTS
    • 12.8.1. COMPANY OVERVIEW
    • 12.8.2. IMMUNO CONCEPTS: COMPANY SNAPSHOT
    • 12.8.3. PRODUCT PORTFOLIO
    • 12.8.4. RECENT DEVELOPMENTS
  • 12.9. INOVA DIAGNOSTICS
    • 12.9.1. COMPANY OVERVIEW
    • 12.9.2. INOVA DIAGNOSTICS:COMPANY SNAPSHOT
    • 12.9.3. PRODUCT PORTFOLIO
    • 12.9.4. RECENT DEVELOPMENTS
  • 12.10. ZEUS SCIENTIFIC, INC.
    • 12.10.1. COMPANY OVERVIEW
    • 12.10.2. ZEUS SCIENTIFIC, INC.: COMPANY SNAPSHOT
    • 12.10.3. PRODUCT PORTFOLIO
    • 12.10.4. RECENT DEVELOPMENTS
  • 12.11. MBL INTERNATIONAL
    • 12.11.1. COMPANY OVERVIEW
    • 12.11.2. MBL INTERNATIONAL: COMPANY SNAPSHOT
    • 12.11.3. PRODUCT PORTFOLIO
    • 12.11.4. RECENT DEVELOPMENTS
  • 12.12. MEDSOURCE OZONE BIOMEDICALS PVT. LTD
    • 12.12.1. COMPANY OVERVIEW
    • 12.12.2. MEDSOURCE OZONE BIOMEDICALS PVT. LTD: COMPANY SNAPSHOT
    • 12.12.3. PRODUCT PORTFOLIO
    • 12.12.4. RECENT DEVELOPMENTS

  • 12.13. AESKU GROUP GMBH & CO. KG
    • 12.13.1. COMPANY OVERVIEW
    • 12.13.2. AESKU GROUP GMBH & CO. KG: COMPANY SNAPSHOT
    • 12.13.3. PRODUCT PORTFOLIO
    • 12.13.4. RECENT DEVELOPMENTS

13. RELATED REPORTS

LIST OF TABLES

TABLE LIST

TABLE 1 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET , BY PRODUCT,

2016 - 2025 (USD MILLION) 57

TABLE 2 ASIA-PACIFIC ASSAY KITS & REAGENTS MARKET, BY REGION,

2016 - 2025 (USD MILLION) 58

TABLE 3 ASIA-PACIFIC SYSTEMS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 59

TABLE 4 ASIA-PACIFIC SOFTWARES MARKET, BY REGION, 2016 - 2025 (USD MILLION) 60

TABLE 5 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET, BY TEST,

2016 - 2025 (USD MILLION) 63

TABLE 6 ASIA-PACIFIC INDIRECT IMMUNOFLUORESCENCE MARKET, BY REGION,

2016 - 2025 (USD MILLION) 64

TABLE 7 ASIA-PACIFIC ELISA MARKET, BY REGION, 2016 - 2025 (USD MILLION) 65

TABLE 8 ASIA-PACIFIC MULTIPLEX TESTING MARKET, BY REGION,

2016 - 2025 (USD MILLION) 66

TABLE 9 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET , BY DISEASE,

2016 - 2025 (USD MILLION) 69

TABLE 10 ASIA-PACIFIC RHEUMATOID ARTHRITIS MARKET, BY REGION,

2016 - 2025 (USD MILLION) 70

TABLE 11 ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, BY REGION,

2016 - 2025 (USD MILLION) 71

TABLE 12 ASIA-PACIFIC SJOGREN'S SYNDROME MARKET, BY REGION,

2016 - 2025 (USD MILLION) 72

TABLE 13 ASIA-PACIFIC SCLERODERMA MARKET, BY REGION,

2016 - 2025 (USD MILLION) 73

TABLE 14 ASIA-PACIFIC POLYMYOSITIS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 74

TABLE 15 ASIA-PACIFIC OTHERS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 75

TABLE 16 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET , BY END USER,

2016 - 2025 (USD MILLION) 78

TABLE 17 ASIA-PACIFIC HOSPITALS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 79

TABLE 18 ASIA-PACIFIC CLINICS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 80

TABLE 19 ASIA-PACIFIC PHYSICIAN OFFICE LABORATORIES MARKET, BY REGION,

2016 - 2025 (USD MILLION) 81

TABLE 20 ASIA-PACIFIC OTHERS MARKET, BY REGION, 2016 - 2025 (USD MILLION) 82

TABLE 21 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET, BY REGION,

2016 - 2025 (USD MILLION) 90

TABLE 22 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY COUNTRY, 2016-2025 (USD MILLION) 157

TABLE 23 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 158

TABLE 24 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 158

TABLE 25 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 159

TABLE 26 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 160

TABLE 27 CHINA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 161

TABLE 28 CHINA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 161

TABLE 29 CHINA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 162

TABLE 30 CHINA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 163

TABLE 31 JAPAN ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 164

TABLE 32 JAPAN ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 164

TABLE 33 JAPAN ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 165

TABLE 34 JAPAN ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 166

TABLE 35 INDIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 167

TABLE 36 INDIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 168

TABLE 37 INDIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 168

TABLE 38 INDIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 169

TABLE 39 SOUTH KOREA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 170

TABLE 40 SOUTH KOREA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 170

TABLE 41 SOUTH KOREA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 171

TABLE 42 SOUTH KOREA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 172

TABLE 43 AUSTRALIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 173

TABLE 44 AUSTRALIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 173

TABLE 45 AUSTRALIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 174

TABLE 46 AUSTRALIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 175

TABLE 47 SINGAPORE ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 176

TABLE 48 SINGAPORE ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 176

TABLE 49 SINGAPORE ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 177

TABLE 50 SINGAPORE ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 178

TABLE 51 THAILAND ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 179

TABLE 52 THAILAND ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 179

TABLE 53 THAILAND ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 180

TABLE 54 THAILAND ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 181

TABLE 55 MALAYSIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 182

TABLE 56 MALAYSIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 182

TABLE 57 MALAYSIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 183

TABLE 58 MALAYSIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 184

TABLE 59 INDONESIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 185

TABLE 60 INDONESIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 185

TABLE 61 INDONESIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 186

TABLE 62 INDONESIA ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 187

TABLE 63 PHILIPPINES ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 188

TABLE 64 PHILIPPINES ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY TEST, 2016 - 2025 (USD MILLION) 188

TABLE 65 PHILIPPINES ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY DISEASE, 2016 - 2025 (USD MILLION) 189

TABLE 66 PHILIPPINES ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY END USER, 2016 - 2025 (USD MILLION) 190

TABLE 67 REST OF ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET ,

BY PRODUCT, 2016 - 2025 (USD MILLION) 191

LIST OF FIGURES

FIGURES LIST

FIGURE 1 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: SEGMENTATION 27

FIGURE 2 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: DATA TRIANGULATION 30

FIGURE 3 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET : RESEARCH SNAPSHOT 31

FIGURE 4 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET : BOTTOM UP APPROACH 32

FIGURE 5 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: TOP DOWN APPROACH 32

FIGURE 6 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET :

INTERVIEW DEMOGRAPHICS 33

FIGURE 7 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET : SEGMENTATION 46

FIGURE 8 ASIA PACIFIC IS THE HIGHEST GROWING AND MOST PROFITABLE REVENUE POCKETS FOR ANTI-NUCLEAR ANTIBODY TEST MANUFACTURERS IN THE FORECAST PERIOD FROM 2018 TO 2025 50

FIGURE 9 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: BY PRODUCT TYPE, 2017 56

FIGURE 10 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: BY TEST, 2017 62

FIGURE 11 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: BY DISEASE, 2017 68

FIGURE 12 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: BY END USER, 2017 77

FIGURE 13 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET SNAPSHOT (2017) 85

FIGURE 14 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: BY GEOGRAPHY (2017) 86

FIGURE 15 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: BY GEOGRAPHY (2018) 87

FIGURE 16 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: BY COUNTRY (2017 & 2025) 88

FIGURE 17 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET:

BY PRODUCT TYPE (2018 & 2025) 89

FIGURE 18 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: SNAPSHOT (2017) 152

FIGURE 19 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: BY COUNTRY (2017) 153

FIGURE 20 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET :

BY COUNTRY (2018 & 2025) 154

FIGURE 21 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY COUNTRY (2017 & 2025) 155

FIGURE 22 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET,

BY PRODUCT (2018 & 2025) 156

FIGURE 23 ASIA-PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET: COMPANY SHARE 2017 (%) 220

FIGURE 24 ASIA PACIFIC ANTI-NUCLEAR ANTIBODY TEST MARKET:

COMPANY SHARE 2017 (%) 223

Back to Top